Literature DB >> 7093959

Development of a new melanoma model in C57BL/6 mice.

J Berkelhammer, R W Oxenhandler, R R Hook, J M Hennessy.   

Abstract

In the present study, we induced melanomas in C57BL/6 mice by a single application of 7,12-dimethylbenz(a)anthracene to the scapular region of 4-day-old mice, followed by twice-weekly applications of croton oil. Of 20 mice treated, melanomas arose in two female littermates. The first melanoma (JB/MS) arose 16 weeks after initiation of treatment, and the second melanoma (JB/RH) arose 23 weeks later. The melanomas maintained their melanotic appearance after s.c. transplantation to normal C57BL/6 mice and metastasized spontaneously in the transplant recipients. To our knowledge, these are the first melanomas to have been induced in C57BL/6 mice since the B16 melanoma arose spontaneously in 1954. We feel that the JB/MS and JB/RH melanomas provide an excellent comparative system for studies done with the B16 melanoma. These melanomas of recent origin will also facilitate the investigation of biological, immunological, and biochemical parameters that influence the growth and metastasis of malignant melanomas.

Entities:  

Mesh:

Year:  1982        PMID: 7093959

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  Photoimmunology of experimental melanoma.

Authors:  C K Donawho; M L Kripke
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

2.  Interferons modulate the expression of hormone receptors on the surface of murine melanoma cells.

Authors:  K Kameyama; S Tanaka; Y Ishida; V J Hearing
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

3.  Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4⁺ and CD8⁺ T cells.

Authors:  Kristan D Guenterberg; Gregory B Lesinski; Bethany L Mundy-Bosse; Volodymyr I Karpa; Alena Cristina Jaime-Ramirez; Lai Wei; William E Carson
Journal:  Cancer Immunol Immunother       Date:  2011-05-21       Impact factor: 6.968

4.  Interferon γ limits the effectiveness of melanoma peptide vaccines.

Authors:  Hyun-Il Cho; Young-Ran Lee; Esteban Celis
Journal:  Blood       Date:  2010-10-01       Impact factor: 22.113

5.  Urokinase-type plasminogen activator-deficient mice are predisposed to staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles.

Authors:  R L Shapiro; J G Duquette; I Nunes; D F Roses; M N Harris; E L Wilson; D B Rifkin
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

Review 6.  In vivo animal models for studying brain metastasis: value and limitations.

Authors:  Inderjit Daphu; Terje Sundstrøm; Sindre Horn; Peter C Huszthy; Simone P Niclou; Per Ø Sakariassen; Heike Immervoll; Hrvoje Miletic; Rolf Bjerkvig; Frits Thorsen
Journal:  Clin Exp Metastasis       Date:  2013-01-16       Impact factor: 5.150

7.  The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse.

Authors:  Gregory B Lesinski; Mirela Anghelina; Jason Zimmerer; Timothy Bakalakos; Brian Badgwell; Robin Parihar; Yan Hu; Brian Becknell; Gerard Abood; Abhik Ray Chaudhury; Cynthia Magro; Joan Durbin; William E Carson
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

8.  Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

Authors:  P O Livingston; E J Natoli; M J Calves; E Stockert; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

Review 9.  The natural history of a family of transplantable melanomas in hamsters.

Authors:  A Bomirski; A Słominski; J Bigda
Journal:  Cancer Metastasis Rev       Date:  1988-06       Impact factor: 9.264

10.  Predominant formation of heavily pigmented dermal melanocytomas resembling 'animal-type' melanomas in hepatocyte growth factor (C57BL/6 x C3H)F1 mice following neonatal UV irradiation.

Authors:  Scott R Florell; Joshua Thomas; Douglas Grossman
Journal:  J Cutan Pathol       Date:  2007-09       Impact factor: 1.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.